The weight-loss drug market has exploded into one of the fastest-growing markets in recent years. Novo Nordisk (NVO) has cemented itself as the leader in the booming weight-loss drug market with blockbuster treatments like Wegovy and Ozempic. However, Eli Lilly (LLY), armed with fast-rising competitors Mounjaro and Zepbound, is mounting a serious challenge. As both companies race to capture a market projected to be worth $381.5 billion by 2033, the battle for dominance is intensifying. Let’s find out whether Novo’s lead is truly secure.
